This database contains 384 studies, archived under the term: "Other"
Click here to filter this large number of results.
The preclinical Alzheimer cognitive composite: Measuring amyloid-related decline
Donohue, Michael C.,
Sperling, Reisa A.,
Salmon, David P.,
Rentz, Dorene M.,
Raman, Rema,
Thomas, Ronald G.,
Weiner, Michael,
Aisen, Paul S
Importance: As Alzheimer disease (AD) research moves to intervene in presymptomatic phases of the disease, we must develop outcome measures sensitive to the earliest disease-related changes. Objective: To demonstrate the feasibility of a cognitive composite outcome for clinically normal elderly participants with evidence of AD pathology using the ADCS Preclinical Alzheimer Cognitive Composite (ADCS-PACC). The […]
Effects of multicomponent exercise on spatial-temporal gait parameters among the elderly with amnestic mild cognitive impairment (aMCI): preliminary results from a randomized controlled trial (RCT)
Doi, Takehiko,
Makizako, Hyuma,
Shimada, Hiroyuki,
Yoshida, Daisuke,
Tsutsumimoto, Kota,
Sawa, Ryuichi,
Misu, Shogo,
Suzuki, Takao
Exercise training has been shown to increase physical function in the elderly. However, the effects of exercise on elderly individuals with amnestic aMCI are unclear. The aim of this RCT was to investigate the effect of multicomponent exercise on gait in the elderly. Fifty elderly individuals with aMCI (age: 65-92 years) participated in the study […]
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer’s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
Dodel, Richard,
Rominger, Axel,
Bartenstein, Peter,
Barkhof, Frederik,
Blennow, Kaj,
Förster, Stefan,
Winter, Yaroslav,
Bach, Jan-Philipp,
Popp, Julius,
Alferink, Judith,
Wiltfang, Jens,
Buerger, Katharina,
Otto, Markus,
Antuono, Piero,
Jacoby, Michael,
Richter, Ralph,
Stevens, James,
Melamed, Isaac,
Goldstein, Jerome,
Haag, Stefan,
Wietek, Stefan,
Farlow, Martin,
Jessen, Frank
Background: Three small trials suggest that intravenous immunoglobulin can affect biomarkers and symptoms of mild-to-moderate Alzheimer’s disease. We tested the safety, effective dose, and infusion interval of intravenous immunoglobulin in such patients.; Methods: We did a multicentre, placebo-controlled phase 2 trial at seven sites in the USA and five in Germany. Participants with probable Alzheimer’s […]
Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: a pilot study
del Ser, Teodoro,
Steinwachs, Klaus C.,
Gertz, Hermann J.,
Andrés, María V.,
Gómez-Carrillo, Belén,
Medina, Miguel,
Vericat, Joan A.,
Redondo, Pilar,
Fleet, David,
Leon, Teresa
This pilot, double-blind, placebo-controlled, randomized, escalating dose trial explored the safety and efficacy of tideglusib, an inhibitor of glycogen synthase kinase-3, in Alzheimer’s disease (AD) patients. Thirty mild-moderate AD patients on cholinesterase inhibitor treatment were administered escalating doses (400, 600, 800, 1,000 mg) of tideglusib or placebo (ratio 2 : 1) for 4, 4, 6, […]
A complex multimodal activity intervention to reduce the risk of dementia in mild cognitive impairment–ThinkingFit: Pilot and feasibility study for a randomized controlled trial
Dannhauser, Thomas M.,
Cleverley, Martin,
Whitfield, Tim J.,
Fletcher, Ben,
Stevens, Tim,
Walker, Zuzana
Background: Dementia affects 35 million people worldwide and is currently incurable. Many cases may be preventable because regular participation in physical, mental and social leisure activities during middle age is associated with up to 47% dementia risk reduction. However, the majority of middle-aged adults are not active enough. MCI is therefore a clear target for […]
Neuromidin in mixed vascular and Alzheimer’s dementia
The efficacy of neuromidin (ipidacrinum), a nonselective inhibitor of acetylcholinesterase and butyrilcholinesterase was studied in patients with mixed vascular and Alzheimer’s dementia of mild and moderate severity. Thirty patients of the main group received neyromidin in dosage 80 mg/day during 3 months; 10 patients of the comparison group matched by age, sex and severity of […]
The FABS trial: a randomised control trial of the effects of a 6-month physical activity intervention on adherence and long-term physical activity and self-efficacy in older adults with memory complaints
Cox, Kay L.,
Flicker, Leon,
Almeida, Osvaldo P.,
Xiao, Jianguo,
Greenop, Kathryn R.,
Hendriks, Jacqueline,
Phillips, Michael,
Lautenschlager, Nicola T.
Objective: The aim of this study is to assess in older adults with memory complaints, the effects of a 6-month home-based physical activity (PA) intervention on short-term adherence, short and long-term self-efficacy and the predictors of adherence.; Methods: Participants with memory complaints with or without mild cognitive impairment (MCI) were recruited from Perth, Western Australia […]
Multivariate spatial covariance analysis of 99mTc-exametazime SPECT images in dementia with Lewy bodies and Alzheimer’s disease: utility in differential diagnosis
Colloby, Sean J,
Taylor, John-Paul,
Davison, Christopher M,
Lloyd, Jim J,
Firbank, Michael J,
McKeith, Ian G,
O'Brien, John T
We examined (99m)Tc-exametazime brain blood flow single-photon emission computed tomography (SPECT) images using a spatial covariance analysis (SCA) approach to assess its diagnostic value in distinguishing dementia with Lewy bodies (DLB) from Alzheimer’s disease (AD). Voxel SCA was simultaneously applied to a set of preprocessed images (AD, n=40; DLB, n=26), generating a series of eigenimages […]